Clicky

Arcturus Therapeutics Ltd.(ARCT)

Description: Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.


Keywords: Biopharmaceutical Drugs Health Sciences Euphoriants Pharmacology Tablet Cognitive Disorders Amphetamine Adhd Glutamate Taar1 Agonists Mdx

Home Page: arcturusrx.com

ARCT Technical Analysis

10628 Science Center Drive
San Diego, CA 92121
United States
Phone: 858 900 2660


Officers

Name Title
Mr. Joseph E. Payne M.Sc. Founder, Pres, CEO & Director
Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, COO & Sec.
Mr. Andrew H. Sassine MBA CFO & Director
Mr. Lance Kurata Chief Legal Officer
Dr. Steven George Hughes M.B.A., M.D. Strategic Clinical Advisor & Member of Scientific Advisory Board
Mr. Keith C. Kummerfeld CPA VP of Fin. & Corp. Controller
Dr. Dushyant B. Varshney Ph.D. Exec. VP & Chief Technology Officer
Mr. Deepankar Roy Sr. Director of Investor Relations
Kyle Gutstadt Sr. Analyst of Investor & PR
Mr. Kevin T. Skol Sr. VP of Bus. Devel. & Alliance Management

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 2.8604
Trailing PE: 0
Price-to-Book MRQ: 3.4283
Price-to-Sales TTM: 9.3831
IPO Date: 2020-04-16
Fiscal Year End: December
Full Time Employees: 177
Back to stocks